Platelet-Derived Thrombogenicity Measured by Total Thrombus-Formation Analysis System in Patients With ST-Segment...

Area of Science:

• Cardiology
• Thrombosis Research
• Interventional Cardiology

Background:

• Effective antiplatelet therapy is crucial for ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PPCI).
• Platelet-derived thrombogenicity during PPCI can influence patient outcomes.
• Assessing thrombogenicity is key to optimizing STEMI management.

Purpose of the Study:

• To evaluate the association between platelet-derived thrombogenicity during PPCI and enzymatic infarct size in STEMI patients.
• To identify determinants of enzymatic infarct size in STEMI patients undergoing PPCI.

Main Methods:

• Platelet-derived thrombogenicity assessed using the total thrombus-formation analysis system (T-TAS) PL-chip (PL18-AUC10) and VerifyNow P2Y12 reaction units (PRU).
• 127 STEMI patients undergoing PPCI were categorized into High and Low PL18-AUC10 groups based on median values.
• Enzymatic infarct size measured by the area under the curve for creatine kinase (AUC_CK).

Main Results:

• High PL18-AUC10 during PPCI was associated with a significantly greater enzymatic infarct size (AUC_CK).
• The High PL18-AUC10 group showed a lower percentage of final Thrombolysis in Myocardial Infarction (TIMI) 3 flow and a higher incidence of slow-flow/no-reflow.
• Multivariate analysis identified high PL18-AUC10 and poor initial TIMI flow as independent determinants of AUC_CK.

Conclusions:

• High platelet-derived thrombogenicity, as measured by T-TAS, during PPCI is significantly associated with larger enzymatic infarct size in STEMI patients.
• These findings underscore the clinical relevance of T-TAS in assessing thrombotic risk and guiding treatment in STEMI.
• Optimizing antiplatelet therapy based on thrombogenicity assessment may reduce infarct size and improve outcomes in STEMI.